development and evaluation of clinical pharmacy services in respiratory diseases

Conditions: Pneumonia; COPD Asthma; COPD Exacerbation

Summary: clinical pharmacists in the healthcare system are experts in therapeutics and the use of drugs. they routinely provide medication reviews and recommendations to patients and healthcare professionals. clinical pharmacists are a scientifically valid source of information and give advice on the safe and appropriate use of medicines and pharmacoeconomics. clinical pharmacist researchers produce, distribute and apply new information that contributes to improving health and quality of life. thus, it is ensured that many of the drug treatment errors that occur after inappropriate therapeutic decisions are made at the point of prescribing are prevented in this investigation, the effects of clinical pharmacists on respiratory would be investigated. this research area will cover lower respiratory tract infections and chronic lung disease exacerbations with icd-10 codes j05, j9-22, j40-47, j69, j85 -j86. in this study, two groups, control and intervention groups, were identified. in the control group; there will be no intervention done by the clinical pharmacist. hospital stay, antimicrobial suitability, microbial resistance development, antimicrobial induced nephrotoxicity, infection-related mortality, pharmacoeconomic evaluation, re-hospitalization within 30 days after discharged, medication reconciliation report will be created, patients will be monitored for the detection and management of drug-related problems will be recorded in both control and intervention groups. in the intervention group; recommendations will be given to the physicians by the clinical pharmacist on the selection of antibiotics, drug suitability, dosage and route of administration advice, and determination of drug-related problems related to drugs used simultaneously.

the literature shows the benefit of including the pharmacist in microbiological test review and follow-up. the inclusion of a pharmacist in antibiotic management processes can result in the more reasonable use of antimicrobial agents and more efficient monitoring with patients and/or caregivers. healthcare policymakers and administrators who evaluate processes to increase efficiency and improve care for patients suspected of discharged infections should examine the effectiveness of clinical pharmacists in the cap. urgent action is needed to tackle the growing resistance threat. antimicrobial stewardship programs (ayp) have resulted in slowing down antimicrobial resistance and improving antimicrobial prescribing practices that can maintain existing antimicrobial treatments. the cdc and joint commission have published recommendations and standards for the conduct of antimicrobial management in both inpatient and outpatient treatment. although the main principles of the program of antimicrobial management have been established for over a decade, ayps are constantly evolving, and improving program efficiency brings new approaches to patient care. although it is one of the main goals of antimicrobial management, the direct effects of ayp interventions on reducing antimicrobial resistance are often immeasurable and multi-factorial. therefore, interventions aimed at minimizing the use of inappropriate antibiotics, including unnecessary and insufficient use, are often used to measure the effect of ayps on resistance. clinical pharmacists in the healthcare system are experts in therapeutics and the use of drugs. they routinely provide medication reviews and recommendations to patients and healthcare professionals. clinical pharmacists are a scientifically valid source of information and give advice on the safe and appropriate use of medicines and pharmacoeconomics. clinical pharmacist researchers produce, distribute and apply new information that contributes to improving health and quality of life. clinical pharmacists care about patients in all healthcare areas. they do not only provide clinical services, but they also provide care to their patients and they can perform this application in any application environment. in other words, clinical pharmacists interact and observe directly with the patient. also, managing treatment directly in patient care settings is particularly important as it reinforces the existing definitions of the term "clinical". in addition, this specialization is used proactively to provide and advance rational drug therapy. thus, it is ensured that many of the drug treatment errors that occur after inappropriate therapeutic decisions are made at the point of prescribing are prevented. in this study, two groups, control and intervention groups, were identified. in the control group; there will be no intervention done by the clinical pharmacist. hospital stay, antimicrobial suitability, microbial resistance development, antimicrobial induced nephrotoxicity, infection-related mortality, pharmacoeconomic evaluation, re-hospitalization within 30 days after discharged, medication reconciliation report will be created, patients will be monitored for the detection and management of drug-related problems will be recorded in both control and intervention groups. in the intervention group; recommendations will be given to the physicians by the clinical pharmacist on the selection of antibiotics, drug suitability, dosage and route of administration advice, and determination of drug-related problems related to drugs used simultaneously.

Eligibility criteria:
inclusion criteria: * having any of the j05, j9-22, j40-47, j69, j85-j86 diagnoses specified in the icd-10 guideline, * patients hospitalized due to respiratory tract infection and using antibiotic drugs, * being 18 years or older, * having signed the written consent form to participate in the study. exclusion criteria: * the consent form is not approved, * not having the necessary cognitive abilities, * being under the age of 18

Keywords: clinical pharmacist drug-related problems chest-diseases cognitive pharmacy services